-
Dec 23 |
Diagnostics World News | Circular Genomics will accelerate the clinical development and commercialization of their circRNA biomarker platform for the early detection of Alzheimer's disease; Wearlinq introduces eWave, the first continuous, multi-lead (6-lead) ECG in a small, wireless form factor; Subsense is building a bidirectional BCI platform designed to record and modulate brain activity without surgical implants; and more.
More
-
Dec 22 |
Diagnostics World News | The Singapore-MIT Alliance for Research and Technology launches a new collaborative research project; Cleveland Diagnostics receives FDA approval of their IsoPSA in vitro diagnostic kit; Roche announces that its first point-of-care test for the detection of Bordetella infections has been granted FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 waiver; and more.
More
-
Dec 18 |
Diagnostics World News | Researchers have identified a previously overlooked mechanism controlling allergic reactions in the gut, potentially paving the way for novel treatments for conditions ranging from food allergies to irritable bowel syndrome.
More
-
Dec 16 |
Diagnostics World News | Good sleep patterns impact many aspects of the broader health status of individuals, but the measurement of slumber quality tends to fall at the extremes of either simplistic sleep logs or cumbersome in-patient sleep studies, or polysomnography. A new sleep-staging framework driven by artificial intelligence and an associated Apple Watch app known as BIDSleep is designed to bridge that gap by turning a smartwatch into a sleep-staging device that can distinguish between light, deep, and rapid eye movement sleep.
More
-
Dec 11 |
Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed.
More
-
Dec 10 |
Diagnostics World News | Thanks to promising developments in psychedelic and dissociative compounds, treatments for depression are likely to significantly change in the next 10 years. However, psychedelics also come with their own set of complications and side effects, such as disconnection from oneself and one’s surroundings and cardiovascular changes.
More
-
Dec 08 |
Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026.
More
-
Dec 04 |
Diagnostics World | When SpaceX’s Inspiration4 lifted off in 2021, it launched new opportunities for commercial space travel and raised new questions about how a space environment impacts the human body. TrialX believes what we learn about biology in space will not only expand our understanding of extreme environments’ impact on human health but will deepen our understanding of how biomarkers and health data are best gathered and explored at home as well.
More
-
Dec 02 |
Diagnostics World | Increasing use of genetic testing to identify people at risk for various diseases has led to a skyrocketing number of never-before-seen variants with uncertain connections to those health conditions, making them impractical to investigate one by one as they once were. Clever bench scientists therefore began making all possible variants in genes with a suspected link to a disease or a patient's symptoms about 15 years ago, to determine which ones are most likely pathogenic.
More
-
Nov 25 |
Diagnostics World | Baylor College of Medicine will continue to create customized cell, fly, and mouse models to study rare genetic diseases; Curve Biosciences will advance the clinical validation and commercialization of their Whole-Body Intelligence platform for chronic disease monitoring; and more.
More
-
Dec 17 |
The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.
More
-
Dec 15 |
Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions
More
-
Dec 15 |
CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.
More
-
Dec 11 |
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.
More
-
Dec 10 |
New York Gastroenterology Associates, LLP (NYGA), New York City’s leading independent gastroenterology practice, is working with Proscia, a pathology AI company, to advance its standard of excellence
More
-
Dec 10 |
New Scale Technologies is announcing the availability of the new DART linear actuator and stage platform.
The DART line is designed to meet the needs of photonic instruments and life science companies looking for smart motion solutions with longer travel and lower cost for high-volume applications. The DART Smart Linear Actuator builds on New Scale’s proprietary SQUIGGLE® technology, offering a greater range of motion and higher force.
More
-
Dec 04 |
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.
More
-
Dec 03 |
Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale
More
-
Nov 26 |
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.
More
-
Nov 21 |
More
View more articles